This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID)
associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in …

Objective. We describe myelodysplastic syndrome (MDS)–associated systemic inflammatory
and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs …

Our objective was to recognize the association of autoimmune diseases (AD) in patients with
myelodysplastic syndromes (MDS) and understand how this association could affect …

In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained
response to azacitidine is increased by maximizing treatment duration. This is important as …

Combination therapy with azacitidine and etanercept was hypothesized to lead to improved
responses in myelodysplastic syndrome (MDS) patients. Thirty‐two patients with …

PURPOSE: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality
from bone marrow failure or transformation to acute leukemia. Supportive care is standard …

Autoimmune disorders (ADs) are encountered in 10 to 20% of patients with myelodysplastic
syndromes (MDS). Available data suggest that ADs concern more often younger patients …

Purpose Within the last two decades, a new understanding of the biology of myelodysplastic
syndrome (MDS) has developed. With this understanding, new classification systems, such …

BACKGROUND: Hypomethylating drugs are useful in the management of myelodysplastic
syndrome (MDS). Two of these drugs, azacitidine and decitabine, have received FDA …

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoeitic
disorders characterized by ineffective hematopoiesis and potential transformation to acute …